Sponsor Deadline
Posted: 4/18/2022

Technologies to Advance Precision Medicine for Reproductive Health and Infertility (R43, R44 Clinical Trial Optional)

The purpose of this funding opportunity announcement (FOA) is to encourage the small business community to collaborate with scientists and clinicians in the fields of female and male reproductive medicine, infertility, andrology/urology, and gynecology to develop, adapt and validate discoveries in genomics, epigenomics, metabolomics and biomarkers to the clinical diagnosis and treatment of women and men with infertility, and diseases and disorders that affect fertility. The ultimate goal is to advance the application of precision medicine to reproductive health through the development of new procedures, assays, digital apps, devices or technologies that improve the specificity, accuracy and rapidity of diagnosis and enhance the individualization, safety and convenience of clinical care.

Deadlines:

  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): July 29, 2021

RFA-HD-22-010 Expiration Date July 30, 2021

Eligibility Requirements

Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.